keyword
https://read.qxmd.com/read/38647433/practical-three-component-regioselective-synthesis-of-drug-like-3-aryl-or-heteroaryl-5-6-dihydrobenzo-h-cinnolines-as-potential-non-covalent-multi-targeting-inhibitors-to-combat-neurodegenerative-diseases
#1
JOURNAL ARTICLE
Hossein Mousavi, Mehdi Rimaz, Behzad Zeynizadeh
Neurodegenerative diseases (NDs) are one of the prominent health challenges facing contemporary society, and many efforts have been made to overcome and (or) control it. In this research paper, we described a practical one-pot two-step three-component reaction between 3,4-dihydronaphthalen-1(2 H )-one ( 1 ), aryl(or heteroaryl)glyoxal monohydrates ( 2a - h ), and hydrazine monohydrate (NH2 NH2 •H2 O) for the regioselective preparation of some 3-aryl(or heteroaryl)-5,6-dihydrobenzo[ h ]cinnoline derivatives ( 3a - h )...
April 22, 2024: ACS Chemical Neuroscience
https://read.qxmd.com/read/38603953/phase-ii-trial-of-pembrolizumab-and-epacadostat-in-recurrent-clear-cell-carcinoma-of-the-ovary-an-nrg-oncology-study-gy016
#2
JOURNAL ARTICLE
Lilian T Gien, Danielle M Enserro, Matthew S Block, Steven Waggoner, Linda R Duska, Andrea E Wahner-Hendrickson, Premal H Thaker, Floor Backes, Michael Kidd, Carolyn Y Muller, Paul A DiSilvestro, Allan Covens, David M Gershenson, Kathleen N Moore, Carol Aghajanian, Robert L Coleman
INTRODUCTION: Early reports of PD-1 inhibition in ovarian clear cell carcinomas (OCCC) demonstrate promising response. We evaluated the combination of pembrolizumab and IDO-1 inhibitor epacadostat in patients with recurrent OCCC. METHODS: This single arm, two-stage, phase 2 trial included those with measurable disease and 1-3 prior regimens. Patients received intravenous pembrolizumab 200 mg every 3 weeks and oral epacadostat 100 mg twice a day. Primary endpoint was overall response rate (ORR), secondary endpoints were toxicity, progression-free survival (PFS) and overall survival (OS)...
April 10, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38474232/myeloid-derived-suppressor-cells-therapeutic-target-for-gastrointestinal-cancers
#3
REVIEW
Junaid Arshad, Amith Rao, Matthew L Repp, Rohit Rao, Clinton Wu, Juanita L Merchant
Gastrointestinal cancers represent one of the more challenging cancers to treat. Current strategies to cure and control gastrointestinal (GI) cancers like surgery, radiation, chemotherapy, and immunotherapy have met with limited success, and research has turned towards further characterizing the tumor microenvironment to develop novel therapeutics. Myeloid-derived suppressor cells (MDSCs) have emerged as crucial drivers of pathogenesis and progression within the tumor microenvironment in GI malignancies. Many MDSCs clinical targets have been defined in preclinical models, that potentially play an integral role in blocking recruitment and expansion, promoting MDSC differentiation into mature myeloid cells, depleting existing MDSCs, altering MDSC metabolic pathways, and directly inhibiting MDSC function...
March 4, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38385162/the-biotherapeutic-clostridium-butyricum-miyairi-588-strain-potentiates-enterotropism-of-ror%C3%AE-t-treg-and-pd-1-blockade-efficacy
#4
JOURNAL ARTICLE
Thomas Paz Del Socorro, Kentaro Oka, Olivier Boulard, Motomichi Takahashi, Lionel Franz Poulin, Atsushi Hayashi, Mathias Chamaillard
Immune checkpoint inhibitors (ICI) have been positioned as a standard of care for patients with advanced non-small-cell lung carcinomas (NSCLC). A pilot clinical trial has reflected optimistic association between supplementation with Clostridium butyricum MIYAIRI 588 (CBM588) and ICI efficacy in NSCLC. However, it remains to be established whether this biotherapeutic strain may be sufficient to heighten the immunogenicity of the tumor draining lymph nodes to overcome resistance to ICI. Herein, we report that supplementation with CBM588 led to an improved responsiveness to antibody targeting programmed cell death protein 1 (aPD-1)...
2024: Gut Microbes
https://read.qxmd.com/read/38382261/indoleamine-2-3-dioxygenase-1-activation-in-macrophage-exacerbates-hepatic-ischemia-reperfusion-injury-by-triggering-hepatocyte-ferroptosis
#5
JOURNAL ARTICLE
Shuoyi Ma, Junjie Li, Haixin Ye, Chaofeng Wu, Jia Zhang, Shu Xu, Yuhong Song, Yong Gu, Lei Gao
BACKGROUND: Hepatic Ischemia-reperfusion (I/R) injury, critical challenge in liver surgery and transplantation, exerts a significant impact on the prognosis and survival of patients. Inflammation and cell death play pivotal roles in pathogenesis of hepatic I/R injury. Indoleamine 2, 3-dioxygenase 1 (IDO-1), a key enzyme involved in the kynurenine pathway, has been extensively investigated for its regulatory effects on innate immune responses and cell ferroptosis. However, the precise involvement of IDO-1 in hepatic I/R injury remains unclear...
February 20, 2024: International Immunopharmacology
https://read.qxmd.com/read/38367683/a-peripheral-blood-mononuclear-cell-based-in-vitro-model-a-tool-to-explore-indoleamine-2-3-dioxygenase-1-ido1
#6
JOURNAL ARTICLE
Milene Gonçalves, Alessia Furgiuele, Emanuela Rasini, Massimiliano Legnaro, Marco Ferrari, Alessandra Luini, Paulo Rodrigues-Santos, Francisco Caramelo, Franca Marino, Frederico C Pereira, Marco Cosentino
BACKGROUND: Proinflammatory cytokines powerfully induce the rate-limiting enzyme indoleamine 2, 3-dioxygenase-1 (IDO-1) in dendritic cells (DCs) and monocytes, it converts tryptophan (Trp) into L-kynurenine (KYN), along the kynurenine pathway (KP). This mechanism represents a crucial innate immunity regulator that can modulate T cells. This work explores the role of IDO1 in lymphocyte proliferation within a specific pro-inflammatory milieu. METHODS: PBMCs were isolated from buffy coats taken from healthy blood donors and exposed to a pro-inflammatory milieu triggered by a double-hit stimulus: lipopolysaccharide (LPS) plus anti-CD3/CD28...
February 15, 2024: European Journal of Pharmacology
https://read.qxmd.com/read/38346604/a-self-assembly-active-nanomodulator-based-on-berberine-for-photothermal-immunotherapy-of-breast-cancer-via-dual-regulation-of-immune-suppression
#7
JOURNAL ARTICLE
Jiang Sun, Tingxian Ye, XinXin Chen, Bin Li, Yinghui Wei, Hangsheng Zheng, Ji-Gang Piao, Fanzhu Li
Breast cancer (BC) remains a significant global health concern, especially affecting women, necessitating the development of effective treatment strategies. Photothermal immunotherapy has holds promise for addressing BC by eradicating tumors, preventing metastasis, and reducing recurrence rates. However, the dynamic amplification of indoleamine 2,3-dioxygenase 1 (IDO-1) and programmed cell death-ligand 1 (PD-L1) triggered by photothermal therapy (PTT) poses presents a significant barrier to immune cell infiltration, thus promoting immune evasion...
February 10, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38322117/exogenous-%C3%AE-ketoglutarate-modulates-redox-metabolism-and-functions-of-human-dendritic-cells-altering-their-capacity-to-polarise-t-cell-response
#8
JOURNAL ARTICLE
Marijana Milanović, Marina Bekić, Jelena Đokić, Dragana Vučević, Miodrag Čolić, Sergej Tomić
Alpha-ketoglutarate (αKG) emerged as a key regulator of energetic and redox metabolism in cells, affecting the immune response in various conditions. However, it remained unclear how the exogenous αKG modulates the functions of dendritic cells (DCs), key cells regulating T-cell response. Here we found that non-toxic doses of αKG display anti-inflammatory properties in human APC-T cell interaction models. In a model of monocyte-derived (mo)DCs, αKG impaired the differentiation, and the maturation of moDCs induced with lipopolysaccharide (LPS)/interferon (IFN)-γ, and decreased their capacity to induce Th1 cells...
2024: International Journal of Biological Sciences
https://read.qxmd.com/read/38231344/bone-marrow-derived-mesenchymal-stromal-cells-obstruct-aml-targeting-cd8-%C3%A2-clonal-effector-and-car-t-cell-function-while-promoting-a-senescence-associated-phenotype
#9
JOURNAL ARTICLE
Russell Towers, Lidia Trombello, Maximilian Fusenig, Antje Tunger, Anna-Lena Baumann, Roberto Savoldelli, Rebekka Wehner, Frederick Fasslrinner, Claudia Arndt, Francesco Dazzi, Malte Von Bonin, Anja Feldmann, Michael P Bachmann, Manja Wobus, Marc Schmitz, Martin Bornhäuser
Bone marrow mesenchymal stromal cells (MSCs) have been described as potent regulators of T-cell function, though whether they could impede the effectiveness of immunotherapy against acute myeloid leukemia (AML) is still under investigation. We examine whether they could interfere with the activity of leukemia-specific clonal cytotoxic T-lymphocytes (CTLs) and chimeric antigen receptor (CAR) T cells, as well as whether the immunomodulatory properties of MSCs could be associated with the induction of T-cell senescence...
January 17, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38188364/investigation-of-tryptophan-to-kynurenine-degradation-in-response-to-interferon-%C3%AE-in-melanoma-cell-lines
#10
JOURNAL ARTICLE
Helena Tassidis, Skaidre Jankovskaja, Kassem Awad, Lars Ohlsson, Anette Gjörloff Wingren, Anna Gustafsson
BACKGROUND AND AIM: Melanoma is a fatal form of skin cancer that carries a grave prognosis if the cancer cells spread and form metastases. The Kynurenine (Kyn) pathway is activated by the enzyme indoleamine 2,3-dioxygenase 1 (IDO-1) and has been shown to have a role in tumour progression. We have previously shown that interferon-γ (IFN-γ) acts as an inducer of tryptophan (Trp) degradation to Kyn in keratinocytes of the basal layer in a 3D epidermis model. Before extending our reconstructed human epidermis model to not only contain keratinocytes but also fibroblasts and melanocytes/melanoma cells, we have in this study set out to investigate possible differences between primary adult melanocytes and six melanoma cell lines regarding the expression of the immune checkpoint inhibitors IDO-1 and programmed death ligand 1 (PD-L1) together with Kyn production...
March 2024: Biochemistry and Biophysics Reports
https://read.qxmd.com/read/37981615/ido-1-impairs-antitumor-immunity-of-natural-killer-cells-in-triple-negative-breast-cancer-via-up-regulation-of-hla-g
#11
JOURNAL ARTICLE
Rui Jing, Shukun Bai, Peipei Zhang, Hao Ren, Lintao Jia, Weimiao Li, Guoxu Zheng
BACKGROUND: Triple-negative breast cancers (TNBC) are highly aggressive malignancies with poor prognosis. As an essential enzyme in the tryptophan-kynurenine metabolic pathway, indoleamine 2,3 dioxygenase-1 (IDO-1) has been reported to facilitate immune escape of various tumors. However, the mechanism underlying the immunosuppressive role of IDO-1 in TNBC remains largely uncharacterized. METHODS: We examined the IDO-1 expression in 93 clinical TNBC tissues and paired adjacent normal tissues, and analyzed the regulation role of environmental cytokines like IFN-γ in IDO-1 expression...
November 19, 2023: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://read.qxmd.com/read/37934691/single-cell-imaging-maps-inflammatory-cell-subsets-to-pulmonary-arterial-hypertension-vasculopathy
#12
JOURNAL ARTICLE
Selena Ferrian, Aiqin Cao, Erin F McCaffrey, Toshie Saito, Noah F Greenwald, Mark R Nicolls, Trevor Bruce, Roham T Zamanian, Patricia Del Rosario, Marlene Rabinovitch, Michael Angelo
Rationale: Elucidating the immune landscape within and surrounding pulmonary arteries (PAs) is critical in understanding immune-driven vascular pathology in pulmonary arterial hypertension (PAH). Although more severe vascular pathology is often observed in hereditary (H)PAH patients with BMPR2 mutations, the involvement of specific immune cell subsets remains unclear. Methods: We used cutting-edge multiplexed ion beam imaging by time-of-flight (MIBI-TOF) to compare PAs and adjacent tissue in PAH lungs (idiopathic (I)PAH and HPAH) with unused donor lungs...
November 7, 2023: American Journal of Respiratory and Critical Care Medicine
https://read.qxmd.com/read/37925676/altered-kynurenine-pathway-metabolism-and-association-with-disease-activity-in-patients-with-systemic-lupus
#13
JOURNAL ARTICLE
Duygu Eryavuz Onmaz, Dilek Tezcan, Sema Yilmaz, Mustafa Onmaz, Ali Unlu
Systemic lupus erythematosus (SLE) is an autoimmune disease accompanied by increased release of proinflammatory cytokines that are known to activate the indoleamine 2,3-dioxygenase (IDO-1) enzyme, which catalyzes the rate-limiting step of the kynurenine pathway (KP). This study aimed to measure KP metabolite levels in patients with SLE and investigate the relationship between disease activity, clinical findings, and KP. The study included 100 patients with SLE and 100 healthy controls. Serum tryptophan (TRP), kynurenine (KYN), kynurenic acid (KYNA), 3-hydroxyanthranilic acid (3HAA), 3-hydroxykynurenine (3HK), quinolinic acid (QA) concentrations were measured with tandem mass spectrometry...
November 5, 2023: Amino Acids
https://read.qxmd.com/read/37895087/pomegranate-peel-extract-differently-modulates-gene-expression-in-gingiva-derived-mesenchymal-stromal-cells-under-physiological-and-inflammatory-conditions
#14
JOURNAL ARTICLE
Miodrag Čolić, Nataša Miljuš, Jelena Đokić, Marina Bekić, Aleksandra Krivokuća, Sergej Tomić, Dušan Radojević, Marina Radanović, Mile Eraković, Bashkim Ismaili, Ranko Škrbić
Pomegranate has shown a favorable effect on gingivitis/periodontitis, but the mechanisms involved are poorly understood. The aim of this study was to test the effect of pomegranate peel extract (PoPEx) on gingiva-derived mesenchymal stromal cells (GMSCs) under physiological and inflammatory conditions. GMSC lines from healthy (H) and periodontitis (P) gingiva ( n = 3 of each) were established. The lines were treated with two non-toxic concentrations of PoPEX (low-10; high-40 µg/mL), with or without additional lipopolysaccharide (LPS) stimulation...
October 21, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37866714/imidazo-2-1-b-thiazole-based-indoleamine-2-3-dioxygenase-ido-1-inhibitor-structure-based-design-synthesis-bio-evaluation-and-docking-studies
#15
JOURNAL ARTICLE
Rahul Singh, Ravinder Kumar, Ashalata Roy, Pabitra Mohan Behera, Ankit K Atri, Kushvinder Kumar, Debasis Manna, Anshuman Dixit, Madhuri T Patil, R Mankamna Kumari, Surendra Nimesh, Deepak B Salunke
Indoleamine-2,3-dioxygenase 1 (IDO1) is an immunomodulatory enzyme known to catalyse the initial and rate limiting step of kynurenine pathway of L-tryptophan metabolism. IDO1 enzyme over expression plays a crucial role in progression of cancer, malaria, multiple sclerosis and other life-threatening diseases. Several efforts over the last two decades have been invested by the researchers for the discovery of different IDO1 inhibitors and the plasticity of the IDO1 enzyme ligand binding pocket provide ample opportunities to develop new heterocyclic scaffolds targeting this enzyme...
October 20, 2023: Bioorganic & Medicinal Chemistry Letters
https://read.qxmd.com/read/37847176/cellular-interactions-in-cell-sheets-enhance-mesenchymal-stromal-cell-immunomodulatory-properties
#16
JOURNAL ARTICLE
Celia M Dunn, Sumako Kameishi, Tavie Parker, Yun-Kyoung Cho, Sun U Song, David W Grainger, Teruo Okano
Immune-related applications of mesenchymal stromal cells (MSCs) in cell therapy seek to exploit immunomodulatory paracrine signaling pathways to reduce inflammation. A key MSC therapeutic challenge is reducing patient outcome variabilities attributed to insufficient engraftment/retention of injected heterogenous MSCs. To address this, we propose directly transplantable human single-cell-derived clonal bone marrow MSC (cBMSC) sheets. Cell sheet technology is a scaffold-free tissue engineering strategy enabling scalable production of highly engraftable cell constructs retaining endogenous cell-cell and -matrix interactions, important to cell function...
October 17, 2023: Tissue Engineering. Part A
https://read.qxmd.com/read/37828996/hypomethylation-induced-regulatory-programs-in-t-cells-unveiled-by-transcriptomic-analyses
#17
JOURNAL ARTICLE
Memnon Lysandrou, Panagiota Stamou, Dionysia Kefala, Chryso Pierides, Maria Kyriakou, Nikolaos Savvopoulos, Panayiota Christofi, Anastasia Papadopoulou, Evangelia Yannaki, Paul Costeas, Alexandros Spyridonidis
Regulatory T cells (Tregs) are essential mediators of tolerance mitigating aberrant immune responses. While naturally occurring Treg (nTreg) development and function are directed by epigenetic events, induced Treg (iTreg) identity and mechanisms of action remain elusive. Mirroring the epigenetic circuits of nTregs, we and others have used hypomethylation agents (HAs) to ex vivo convert T cells into iTregs (HA-iTregs) and further showed that the suppressive properties of the HA-iTregs are predominantly confined in an emergent population, which de novo expresses the immunomodulatory molecule HLA-G, consequently providing a surface marker for isolation of the suppressive HA-iTreg compartment (G+ cells)...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37782060/prognostic-value-of-indoleamine-2-3-dioxygenase-1-expression-in-glial-tumors
#18
JOURNAL ARTICLE
Munir Kaya, Asude Aksoy, Gokhan Artas, Metin Kaplan
BACKGROUND AND PURPOSE: <p>Gliomas are the most common primary malignant central nervous system tumors in adults, exhibiting a poor prognosis. Indoleamine 2, 3-dioxygenase-1 (IDO-1) has important functions in cancer immunotherapy due to its role in escaping cancer cells from the immune system. In this study we purposed to evaluate the correlation between IDO-1 expression and clinicopathological parameters in gliomas, and whether IDO-1 can be a prognostic marker.</p>. METHODS: <p>n=75 patients in total, n=25 patients with low grade glial tumors (LGG, grade 1-2), n=25 patients with high grade glial tumors (HGG, grade 3-4), and n=25 persons with normal brain tissue as control group were included in this study...
September 30, 2023: Ideggyógyászati Szemle
https://read.qxmd.com/read/37767907/multifunctional-nanoassembly-for-mri-trackable-dendritic-cell-dependent-and-independent-photoimmunotherapy
#19
JOURNAL ARTICLE
Bing Xiao, Hongxia Xu, Xiaodan Xu, Yixuan Pan, Xueying Shi, Pengcheng Yuan, Nigel K H Slater, Wenjing Sun, Jianbin Tang, Youqing Shen, Jianqing Gao
Immunotherapy has emerged as a triumph in the treatment of malignant cancers. Nevertheless, current immunotherapeutics are insufficient in addressing tumors characterized by tumor cells' inadequate antigenicity and the tumor microenvironment's low immunogenicity (TME). Herein, we developed a novel multifunctional nanoassembly termed FMMC through the self-assembly of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor 1-methyl-tryptophan prodrug (FM), Ce6, and ionic manganese (Mn2+ ) via noncovalent interactions...
September 28, 2023: Nano Letters
https://read.qxmd.com/read/37751001/potential-involvement-of-il-32-in-cell-to-cell-communication-between-macrophages-and-hepatoblastoma
#20
JOURNAL ARTICLE
Ahmad Adawy, Lianbo Li, Hiroki Hirao, Tomoaki Irie, Daiki Yoshii, Hiromu Yano, Yukio Fujiwara, Shigeyuki Esumi, Masaki Honda, Shinya Suzu, Yoshihiro Komohara, Taizo Hibi
PURPOSE: This study investigated the expression of interleukin 32 (IL-32) in hepatoblastoma, the most common primary pediatric liver tumor, and its possible roles in tumorigenesis. METHODS: IL-32 expression was investigated in two hepatoblastoma cell lines (Hep G2 and HuH 6) in the steady state and after co-culture with macrophages by RNA-seq analysis and RT-qPCR, and after stimulation with chemotherapy. Cultured macrophages were stimulated by IL-32 isoforms followed by RT-qPCR and western blot analysis...
September 26, 2023: Pediatric Surgery International
keyword
keyword
169406
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.